Protagonist Therapeutics Files 8-K on Financials
Ticker: PTGX · Form: 8-K · Filed: Aug 6, 2025 · CIK: 1377121
Sentiment: neutral
Topics: financial-reporting, sec-filing
TL;DR
Protagonist Therapeutics filed an 8-K on Aug 6, 2025, covering financial results and exhibits.
AI Summary
Protagonist Therapeutics, Inc. filed an 8-K on August 6, 2025, reporting on its results of operations and financial condition, as well as financial statements and exhibits. The filing does not contain specific financial figures or operational updates beyond the reporting of these items.
Why It Matters
This 8-K filing indicates Protagonist Therapeutics is providing updates on its financial condition and operations to the SEC, which is standard for public companies.
Risk Assessment
Risk Level: low — This is a routine 8-K filing for financial reporting and does not indicate any unusual events or risks.
Key Players & Entities
- Protagonist Therapeutics, Inc. (company) — Registrant
- August 6, 2025 (date) — Date of Report
- Delaware (jurisdiction) — State of Incorporation
- 7707 Gateway Blvd., Suite 140 (address) — Business Address
- Newark, CA (location) — Business Address City and State
FAQ
What specific financial results are being reported in this 8-K?
The filing states it is reporting on 'Results of Operations and Financial Condition' but does not provide specific figures within the provided text.
What exhibits are included with this 8-K filing?
The filing indicates 'Financial Statements and Exhibits' are included, but the specific exhibits are not detailed in the provided text.
When was this 8-K report filed?
The report was filed on August 6, 2025.
What is the primary business of Protagonist Therapeutics, Inc.?
Protagonist Therapeutics, Inc. is in the 'PHARMACEUTICAL PREPARATIONS' industry, SIC code 2834.
Where is Protagonist Therapeutics, Inc. headquartered?
The company's business address is 7707 Gateway Blvd., Suite 140, Newark, CA 94560-1160.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on August 6, 2025 regarding Protagonist Therapeutics, Inc (PTGX).